Ramakrishna Somashekara H, Katheresan Vellaichamy, Kasala Mohan B, Perumal Karnan, Malleeswaran Selvakumar, Varghese Joy, Patcha Rajanikanth V, Bachina Prashant, Madhavapeddy Poushya S, Reddy Mettu S
Department of Pediatric Hepatology & Transplant Hepatology, Rainbow Children's Hospital, Marathahalli, Bangalore, India.
Department of Pediatric Hepatology, Gleneagles Global Health City, Perumbakkam, Chennai, India.
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102560. doi: 10.1016/j.jceh.2025.102560. Epub 2025 Mar 27.
Liver transplantation (LT) is indicated for children with Wilson's disease (WD) presenting with acute liver failure (ALF) or with chronic liver disease (CLD) that has progressed to decompensation. We present our experience of living donor liver transplantation (LDLT) for pediatric WD, discuss the challenges of managing WD-ALF and compare outcomes of children presenting with WD-ALF with WD-CLD.
We compared presentation and outcomes of the WD-ALF and WD-CLD cohorts. Fifty-three children (WD-ALF: 28 (53%), WD-CLD: 25 (47%)) underwent LDLT for WD.
WD-ALF group had higher Kings New Wilson Index (KNWI) (15 vs 9, = 0.001), higher pediatric end-stage liver disease/model for end-stage liver disease score (35 vs 20, = 0.001), were more frequently encephalopathic (64% vs 4%, = 0.001), and had ongoing hemolysis (86% vs 28%, <0.001). Preoperative mechanical ventilation, operative continuous renal replacement therapy (CRRT), therapeutic plasma exchange (TPE) was needed in 32%, 46.5%, and 89% of WD-ALF children, respectively. WD-ALF patients had longer postoperative ICU stay (4.5 days vs 3 days, = 0.001), longer hospital stay (20.5 days vs 14 days, = 0.001), more major complications (57% vs 20%, = 0.006). WD-ALF cohort also had more postoperative neurological complications (42.9% vs 8%, = 0.004) and invasive fungal infections (21.4% vs none, = 0.024). There were two perioperative (90 day) mortalities in WD-ALF group and none in WD-CLD group. Patient survival of the entire cohort at median follow-up of 26 months was 94.3% and all survivors had good allograft function neurological sequelae. Patient survival was inferior for WD-ALF cohort though the difference was not statistically significant (88.5% vs 100%, log rank test, = 0.089).
LDLT is a curative treatment for children with WD with excellent short-term and long-term outcomes. WD-ALF patients can have a complicated postoperative course but have good long-term survival.
对于患有威尔逊病(WD)且出现急性肝衰竭(ALF)或已进展至失代偿期的慢性肝病(CLD)的儿童,需进行肝移植(LT)。我们介绍了小儿WD活体肝移植(LDLT)的经验,讨论了WD-ALF管理中的挑战,并比较了WD-ALF患儿与WD-CLD患儿的结局。
我们比较了WD-ALF和WD-CLD队列的表现和结局。53名儿童(WD-ALF:28名(53%),WD-CLD:25名(47%))接受了WD的LDLT。
WD-ALF组的金斯新威尔逊指数(KNWI)更高(15对9,P = 0.001),小儿终末期肝病/终末期肝病模型评分更高(35对20,P = 0.001),更频繁出现脑病(64%对4%,P = 0.001),且持续存在溶血(86%对28%,P<0.001)。分别有32%、46.5%和89%的WD-ALF儿童术前需要机械通气、术中需要连续性肾脏替代治疗(CRRT)、治疗性血浆置换(TPE)。WD-ALF患者术后在重症监护病房的停留时间更长(4.5天对3天,P = 0.001),住院时间更长(20.5天对14天,P = 0.001),主要并发症更多(57%对20%,P = 0.006)。WD-ALF队列术后的神经并发症也更多(42.9%对8%,P = 0.004)和侵袭性真菌感染更多(21.4%对无,P = 0.024)。WD-ALF组有2例围手术期(90天)死亡,WD-CLD组无死亡。整个队列在中位随访26个月时的患者生存率为94.3%,所有幸存者的移植肝功能良好且无神经后遗症。WD-ALF队列的患者生存率较低,尽管差异无统计学意义(88.5%对100%,对数秩检验,P = 0.089)。
LDLT是治疗小儿WD的一种治愈性方法,具有出色的短期和长期结局。WD-ALF患者术后病程可能复杂,但长期生存率良好。